Krsnaa Diagnostics Q3 FY26: Revenue Up 4% to ₹1,812 Crore, PAT at ₹168 Crore
Krsnaa Diagnostics reported Q3 FY26 consolidated revenue of ₹1,812 crore, up 4% YoY. Normalised PAT was ₹168 crore. For 9M FY26, revenue grew 9% to ₹5,802 crore, and PAT increased 5% to ₹597 crore. The company is expanding its network with over 200 CT/MRI centers planned and launched its first Apulki Healthcare Hospital.
The results show steady growth and expansion, which are positive indicators. However, the slight dip in PAT for the quarter and the overall moderate growth rates suggest a medium impact rather than high.
The company reported revenue growth in Q3 FY26 and 9M FY26, along with expansion plans for its diagnostic network and the launch of a new healthcare facility, indicating positive business development.
Krsnaa Diagnostics Limited has released its investor presentation for the quarter and nine months ended December 31, 2025 (Q3 FY26). The company reported a consolidated revenue from operations of ₹1,812 crore for Q3 FY26, a 4% increase compared to ₹1,745 crore in Q3 FY25. Normalised EBITDA stood at ₹484 crore, also a 4% rise year-on-year. Normalised PAT for the quarter was ₹168 crore, a marginal 1% decrease from ₹169 crore in the previous year's corresponding quarter. Normalised EBITDA margin remained stable at 27%, while Normalised PAT margin saw a slight decrease to 9% from 10% in Q3 FY25.
For the nine-month period ended December 31, 2025 (9M FY26), consolidated revenue grew by 9% to ₹5,802 crore from ₹5,311 crore in 9M FY25. EBIDTA increased by 13% to ₹1,600 crore, and PAT rose by 5% to ₹597 crore. The company also highlighted its growth in the retail segment, with retail revenue contributing 28% to group revenue in Q3 FY26, up from 32% in Q3 FY25, and a reported Y-o-Y retail business revenue increase of approximately 8x.
The company is expanding its network of diagnostic centers and labs. As of Q3 FY26, it operates 149 CT centers (up from 139 in Q3 FY25), 41 MRI centers (up from 39), and 4,034 Satellite Lab Collection Centres (up from 3,544). Upon completion of its existing order book, Krsnaa Diagnostics expects to have over 200 CT/MRI centers, positioning itself as one of Asia's largest radiology players. The Rajasthan project is set to expand its pathology network to 49 Reference Labs, 249 Satellite Labs, and over 5,000 Collection Centres.
Krsnaa Diagnostics also announced the launch of its first Apulki Healthcare Hospital, a 150-bed facility in association with Pune Municipal Corporation, offering cancer and cardiac care services under a PPP model. The company has also received approval to operationalize four more hospitals with a capacity of 600 beds. The company emphasizes its competitive advantage through affordable pricing, offering services at 50-70% lower than peers, and its extensive reach across 18 states and union territories, having served over 81 million patients since inception.
What to do with a filing like this
Krsnaa Diagnostics Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Krsnaa Diagnostics Limited. Read the original for the full detail.